Contact Information

support@thebignews.com.ng

We Are Available 24/ 7. Call Now.

NAFDAC denies approving pax herbal product for treatment of Covid-19.
The National Agency for Food and Drug Administration and Control (NAFDAC) said yesterday that they are currently processing 21 herbal medicinal products for “Safe to use” or Listing status which most of the applicants claimed are immune boosters and anti- infectives, useful for release of symptoms that could be associated with Covid-19.
The agency warned that until a clinical study is done in a scientific manner, no herbal medicine medicine manufacturer can claim effectiveness to treat the symptoms of corona virus.
In a statement yesterday in Abuja, Director General of NAFDAC, Prof Mojisola Adeyeye described the circulations going on social media as inaccurate and also explained that no clinical study has been done yet on any of the products to prove their claim of efficacy adding that listing status involves the review of the composition of the formulation, the labelling of the product, the process of manufacture and “Safe to use” testing adding that the listing of a herbal product is not a herbal product is not a requirement for the conduct of Clinicals Trials.
She said:
” Once the product is able to meet all requirements, a listing status is granted with a clear disclaimer that states clearly that claims have not been evaluated by NAFDAC. The applicant can arrange for clinical trials that will involve use of human subjects in order to prove claim for treatment following laid down procedures and with the approval of NAFDAC.
“Most of the applicants that submitted herbal medicines that are currently undergoing processing have been issued compliance directives to provide additional information or/and evidence of Good Manufacturing Practice or environment fit for production of the medicines.
“Paxherbal applied for Listing of Pax Herbal Cugzin capsule 290mg which was approved by NAFDAC and listed as “safe to use” .
The applicant claimed that it is an immune boosters and anti- infective. However, as part of the labelling of the product, and in line with global practice, a disclaimer is on the product label which clearly states that the claims have not been evaluated by NAFDAC”.

Share:

Leave a Reply

Your email address will not be published. Required fields are marked *